Intestinal Perforation in a patient with peritoneal carcinomatosis from colon cancer treated with Regorafenib. Description of a case and review of the literature

Intestinal Perforation in a patient with peritoneal carcinomatosis from colon cancer treated with Regorafenib. Description of a case and review of the literature

Regorafenib is a multikinase inhibitor approved for treatment of patients with metastatic Colo-Rectal Cancer (mCRC) and Gastro-Intestinal Stromal Tumor (GIST) progression after the administration of other tyrosine-kinase inhibitors such as imatinib and sunitinib.Only a handful of severe side effects...

Full description

Bibliographic Details
Main Authors: Maria Alessandra Bellia, Carmelo Sofia, Maria Adele Marino, Carmelo Mazzeo, Santino Antonio Biondo, Eugenio Cucinotta, Francesco Fleres
Format: Article
Language:English
Published: Elsevier 2024-05-01
Series:Radiology Case Reports
Subjects:
Colon cancer
Peritoneal metastases
Intestinal perforation
Regorafenib
Chemotherapy induced adverse event
Online Access:http://www.sciencedirect.com/science/article/pii/S1930043324001092

Similar Items

Similar Items